BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Pharma Research

BioMed X Institute and Merck KGaA, Extend Collaboration in Oncology

German independent research institute BioMed X announces today the extension of its collaboration with Merck KGaA, Darmstadt, Germany, in the res...

February 01, 2022 | News

Debiopharm and Aspen Partner to launch prostate cancer drug trelstar® in South Africa

In 2020, nearly 14,000 South African men were newly diagnosed with prostate cancer1 with an average of 5 men dying from the disease every day.2 I...

February 01, 2022 | News

BeiGene Announces Acceptance of Supplemental New Drug Application in China

BRUKINSA was granted its first breakthrough therapy designation in China with this application The application is supported by SEQUOIA trial results, whic...

January 31, 2022 | News

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab

Lonza to manufacture drug substance for clinical supply of HaemaLogiX's lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facil...

January 28, 2022 | News

Beijing Handian Pharamceutical Held an Expert Seminar About TCM Global Application In Beijing

he seminar first discussed the main reason causes the traditional Chinese medicine hardly used in other countries, which including the complex and rich eff...

January 27, 2022 | News

Illumina collaborates with National Cancer Center Japan to address a leading cause of death in Asia

Illumina, Inc. (NASDAQ: ILMN) and the National Cancer Center Japan have announced an international joint research project that will use Illumina's hig...

January 25, 2022 | News

AHF Praises Merck for Generics – Urges Same from Vaccine Makers

“We praised Merck last October for its voluntary licensing agreement with MPP. Their efforts are now coming to fruition with an affordable ...

January 25, 2022 | News

ImmVira's New-Generation Vector Poised to Enable CAR-T Treatment for Solid Tumors

Solid tumor has long been a challenge for CAR-T. Major obstacles include solid tumor heterogeneity, lack of tumor associated antigens as CAR-T targets, com...

January 25, 2022 | News

Natera's Signatera™ MRD Test is Predictive of Chemotherapy Benefit in Colorectal Cancer

Analysis of 1,000+ patients, with 12 months mean follow up, demonstrates clinical utility of Signatera for informing post-surgical treatment decisions &nb...

January 24, 2022 | News

Sihuan Pharmaceutical Establishment of Joint Venture with Bluepha Co., Ltd

Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as ...

January 21, 2022 | News

CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation

Mr. Daly will lead the CARsgen U.S. team for the international business activities of CARsgen outside of China, including clinical development, CMC op...

January 19, 2022 | News

Piramal Pharma Solutions Strengthens North American Capabilities

The Pharma Solutions (PPS) division of Piramal Enterprises Limited, a leading research, development and contract manufacturing (CDMO) organization, today...

January 14, 2022 | News

China Based Gracell Biotechnologies Unveils Innovation Center in U.S.

As a pivotal part of Gracell's global strategy, the company is fully committed to expanding its operations in the U.S. to enhance and diversify its in-hous...

January 13, 2022 | News

CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA

With the RMAT designation, CT041 enjoys all the benefits of Fast Track and Breakthrough Therapy designations including early and intensive FDA guidance on ...

January 11, 2022 | News

Stay Connected